×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
HOTH – hoth therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
HOTH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/26
08:30 am
hoth
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
High
Report
Hoth Therapeutics Deploys OpenClaw™ AI Platform to Accelerate Drug Discovery
3/25
11:17 am
hoth
Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.
Low
Report
Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.
3/24
08:39 am
hoth
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [Yahoo! Finance]
Low
Report
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [Yahoo! Finance]
3/24
08:29 am
hoth
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [TheStreet.com]
Low
Report
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption [TheStreet.com]
3/24
08:13 am
hoth
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
Medium
Report
Hoth Therapeutics Reports Positive HT-001 PK, Safety, and Clinical Activity Data in Cancer Patients with EGFR Therapy-Associated Skin Toxicities Showing ~77% Increase in Drug Exposure and Minimal Systemic Absorption
3/10
08:39 am
hoth
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model [Yahoo! Finance]
Low
Report
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model [Yahoo! Finance]
3/10
08:13 am
hoth
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
Low
Report
Hoth Therapeutics Reports Positive Female Preclinical Data Showing HT-VA Restores Cholesterol Levels and Improves Lipid Metabolism in MASLD Model
3/4
02:49 pm
hoth
Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.
Neutral
Report
Hoth Therapeutics (HOTH) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $5.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Hoth Therapeutics Announces Agreement to Joint Development of a Self-Assembling Vaccine (SAV) for the Potential Treatment of the Coronavirus (COVID-19)
38.5%
4/22 Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate 30.8%
2/4 Hoth Initiates Preclinical Gene Therapy Program with NC State for the Treatment of Asthma and Allergic Inflammation 16.0%
11/26 Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy 15.9%
6/27 Hoth Therapeutics, Inc. Enters into Sponsored Research Agreement with the George Washington University 12.8%
12/26 Form 4 Hoth Therapeutics, Inc. For: Dec 24 Filed by: Hayes Anthony 11.5%
4/24 Voltron Therapeutics, Inc. Announces Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine 8.8%
8/23 Form 8-K Hoth Therapeutics, Inc. For: Aug 19 7.9%
6/11 Biotech Brief: Atopic Dermatitis (Eczema) Revenues Projected to Exceed $6 Billion by 2022 7.4%
4/3 Form S-1 Hoth Therapeutics, Inc. 7.3%
4/22 Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate 30.8%
2/4 Hoth Initiates Preclinical Gene Therapy Program with NC State for the Treatment of Asthma and Allergic Inflammation 16.0%
11/26 Hoth Therapeutics and North Carolina State University Enter License Agreement for Gene Therapy 15.9%
6/27 Hoth Therapeutics, Inc. Enters into Sponsored Research Agreement with the George Washington University 12.8%
12/26 Form 4 Hoth Therapeutics, Inc. For: Dec 24 Filed by: Hayes Anthony 11.5%
4/24 Voltron Therapeutics, Inc. Announces Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of a COVID-19 Vaccine 8.8%
8/23 Form 8-K Hoth Therapeutics, Inc. For: Aug 19 7.9%
6/11 Biotech Brief: Atopic Dermatitis (Eczema) Revenues Projected to Exceed $6 Billion by 2022 7.4%
4/3 Form S-1 Hoth Therapeutics, Inc. 7.3%
TOP News Decliners
3/23
Hoth Therapeutics inks deal to develop vaccine for Covid-19 [Seeking Alpha]
-38.3%
3/27 HaloVax™ Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection -21.8%
4/23 REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate -19.8%
3/23 Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock -15.8%
7/22 Biotech Brief: Reports Forecast Continued Rise in Revenues for Diabetic Ulcer Treatment Market -14.7%
8/30 Form S-1 Hoth Therapeutics, Inc. -12.0%
3/4 Form SC 13G Hoth Therapeutics, Inc. Filed by: EITNER MATTHEW D. -8.6%
9/6 Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference -8.5%
10/25 Form 424B3 Hoth Therapeutics, Inc. -7.9%
3/16 Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share -7.7%
3/27 HaloVax™ Announces Agreement with Hoth Therapeutics to Joint Develop a Self-Assembling Vaccine (SAV) to Protect Patients at Risk of Coronavirus (COVID-19) Infection -21.8%
4/23 REMINDER: Hoth Therapeutics to Host Shareholder Update Conference Call with Dr. Mark Poznansky to Discuss COVID-19 Vaccine Candidate, VaxCelerate -19.8%
3/23 Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock -15.8%
7/22 Biotech Brief: Reports Forecast Continued Rise in Revenues for Diabetic Ulcer Treatment Market -14.7%
8/30 Form S-1 Hoth Therapeutics, Inc. -12.0%
3/4 Form SC 13G Hoth Therapeutics, Inc. Filed by: EITNER MATTHEW D. -8.6%
9/6 Hoth Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference -8.5%
10/25 Form 424B3 Hoth Therapeutics, Inc. -7.9%
3/16 Diamond Equity Research Publishes Report Valuing HOTH Common Stock at $7.00 Per Share -7.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: